Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | PTPRB | P23467 | 1/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PTPRA | P18433 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8226063 | 0.91 | PLAU (0.46) | SMN1; SMN2LMNAPLAUHTTALDH1A1 | |
| SCHEMBL6318265 | 0.87 | KMT2A (0.41) | SMN1; SMN2HTTALDH1A1MAPTTGM2 | |
| SCHEMBL6318762 | 0.84 | HSD17B10 (0.45) | HTTALDH1A1HDAC1MAPTPTPN2 | |
| SCHEMBL6316825 | 0.83 | HSD17B10 (0.48) | SMN1; SMN2LMNAHTTALDH1A1MAPT | |
| SCHEMBL6310340 | 0.83 | LMNA (0.49) | SMN1; SMN2LMNAALDH1A1MAPTNPSR1 | |
| SCHEMBL6313108 | 0.81 | MEN1 (0.38) | SMN1; SMN2HTTALDH1A1MAPTPTPN2 | |
| SCHEMBL7516389 | 0.81 | ALDH1A1 (0.40) | SMN1; SMN2LMNAHTTALDH1A1HDAC1 | |
| SCHEMBL6317833 | 0.79 | NPSR1 (0.55) | SMN1; SMN2LMNAALDH1A1MAPTNPSR1 | |
| SCHEMBL7686880 | 0.79 | KMT2A (0.41) | SMN1; SMN2PLAUHTTMAPTTGM2 | |
| SCHEMBL7525566 | 0.79 | SMN1; SMN2 (0.41) | SMN1; SMN2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020002199-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | US | claimed |
| US-20050119332-A1 | Substituted thiophene compounds as modulators of protein tyrosine phosphatases (PTPases) | JEPPESEN LONE (DK) | 2005-06-02 | — | — | US | disclosed |
| US-20020165398-A1 | Modulators of protein tyrosine phosphatases (PTPases) | JEPPESEN LONE (DK) | 2002-11-07 | — | — | US | disclosed |
| US-20020002199-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165398-A1 | Modulators of protein tyrosine phosphatases (PTPases) | PTPRCAP, PTPRS, PTPRO | SMN1; SMN2 1660/4885LMNA 4790/4885PLAU 1095/4885 |
| US-20020002199-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | PTPRCAP, PTPRS, PTPRA | SMN1; SMN2 1576/4885LMNA 4783/4885PLAU 1111/4885 |
| US-20050119332-A1 | Substituted thiophene compounds as modulators of protein tyrosine phosphatases (PTPases) | PTPRCAP, PTPRS, PTPN1 | SMN1; SMN2 1880/4885LMNA 4870/4885PLAU 2999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.